VectorY Therapeutics

The growing competition between Novo Nordisk and Eli Lilly in diabetes and obesity has been one of the biggest stories of 2023, and venture capital firm Forbion has been a major beneficiary, selli

The mood around the BIO-Europe conference in Munich in November was positive as people in the biotech world, or at least 5,500 of them, gathered to talk shop at over 30,000 partnering meetings. Howeve

Gilde Healthcare, a venture capital and private equity firm with more than €2.5bn in invested capital, closed its Gilde Healthcare Venture&Growth VI Fund with €740m ($806.5m) in commitments, building

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Sol-Gel Hopes To Bring PellePharm’s Pat